XLON
NIOX
Market cap374mUSD
Oct 09, Last price
67.60GBP
1D
-0.30%
1Q
17.07%
Jan 2017
-28.51%
IPO
-78.32%
Name
Niox Group PLC
Chart & performance
P/E
40.65
P/S
5.84
EPS
0.02
Div yield, %
1.86%
Shrs. gr., 5y
-0.77%
Rev. gr., 5y
9.24%
Revenues
49m
+16.49%
Net income
7m
+89.16%
CFO
16m
-8.15%
Dividend
May 21, 20261.55 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxide (FeNO) measurements. The company was founded by Steven Harris and Charles Stuart Webb Swingland on May 19, 2006 and is headquartered in Oxford, the United Kingdom.
Related entities
Subsidiaries
NIOX HEALTHCARE LIMITED
Key people
Non-Executive Chairman of the Board · since 2025
Stewart Sharpe
Vice President - Commercial Operations · since 2012
Sarah Duncan
Chief Financial Officer, Executive Director · since 2025
Jonathan Emms
Chief Executive Officer, Executive Director · since 2025
Nicholas Mills
Non-Independent Non-Executive Director · since 2020
Non-Executive Independent Director · since 2018
Robert Naylor
Non-Executive Independent Director · since 2024
Senior Non-Executive Independent Director · since 2020
Headquarters & legal address
MAGDALEN CENTRE
1 ROBERT ROBINSON AVE
The Oxford Science Park
OXFORD, OXF OX4 4GA
GB
1 ROBERT ROBINSON AVE
The Oxford Science Park
OXFORD, OXF OX4 4GA
GB
Previous name
CIRCASSIA GROUP PLC
Previous name
CIRCASSIA PHARMACEUTICALS PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑12 | 2022‑12 | 2022‑12 | 2021‑12 | 2021‑12 | 2020‑12 | 2020‑12 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑12 | 2016‑12 | 2016‑12 | |
| Income | ||||||||||||||||||
Revenues | ||||||||||||||||||
Cost of revenue | ||||||||||||||||||
Unusual Expense (Income) | ||||||||||||||||||
NOPBT | ||||||||||||||||||
NOPBT Margin | ||||||||||||||||||
Operating Taxes | ||||||||||||||||||
Tax Rate | ||||||||||||||||||
NOPAT | ||||||||||||||||||
Net income | ||||||||||||||||||
Dividends | ||||||||||||||||||
Dividend yield | ||||||||||||||||||
Proceeds from repurchase of equity | ||||||||||||||||||
BB yield | ||||||||||||||||||
| Debt | ||||||||||||||||||
Debt current | ||||||||||||||||||
Long-term debt | ||||||||||||||||||
Deferred revenue | ||||||||||||||||||
Other long-term liabilities | ||||||||||||||||||
Net debt | ||||||||||||||||||
| Cash flow | ||||||||||||||||||
Cash from operating activities | ||||||||||||||||||
CAPEX | ||||||||||||||||||
Cash from investing activities | ||||||||||||||||||
Cash from financing activities | ||||||||||||||||||
FCF | ||||||||||||||||||
| Balance | ||||||||||||||||||
Cash | ||||||||||||||||||
Long term investments | ||||||||||||||||||
Excess cash | ||||||||||||||||||
Stockholders' equity | ||||||||||||||||||
Invested Capital | ||||||||||||||||||
ROIC | ||||||||||||||||||
ROCE | ||||||||||||||||||
| EV | ||||||||||||||||||
Common stock shares outstanding | ||||||||||||||||||
Price | ||||||||||||||||||
Market cap | ||||||||||||||||||
EV | ||||||||||||||||||
EBITDA | ||||||||||||||||||
EV/EBITDA | ||||||||||||||||||
Interest | ||||||||||||||||||
Interest/NOPBT | ||||||||||||||||||